Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2025
Event: Update on the INVINCIBLE-4 clinical study for the investigational product INT230-6.
Key Financial Metrics
This filing is a current report regarding clinical trial progress and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
- Study Progress: A pathological complete response (pCR) was observed in the first patient evaluated in Cohort A of the INVINCIBLE-4 study.
- Treatment Protocol: Patients in Cohort A received two doses of INT230-6 eight days apart, followed by standard of care immunochemotherapy.
- Safety Profile: The overall safety profile in Cohort A is reported as favorable.
- Adverse Events: Some patients experienced localized skin irritation near the tumor site.
- Operational Impact: New patient enrollment has been paused to evaluate collected data and implement necessary adjustments before reopening.
Outlook, Risks, and Management Commentary
Management has paused enrollment to address localized skin irritation observed in Cohort A. The company intends to evaluate data and implement adjustments prior to resuming patient enrollment. No specific financial guidance or long-term outlook was provided in this filing.
Key Facts for Investor Verification
- Confirmation of the timeline for resuming patient enrollment in the INVINCIBLE-4 study.
- Details on the specific adjustments being implemented to mitigate skin irritation.
- Impact of the enrollment pause on the study's projected completion date.
- Current cash runway and funding status, given the company is an emerging growth company with no revenue reported in this filing.